The valsartan antihypertensive longterm use evaluation (VALUE) trial: Final patients demographics
نویسندگان
چکیده
منابع مشابه
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan- or amlodipine-based regimens. In this report, we analyzed outcomes in 7080 patients (46.4%) who, at the end of the initial drug adjustment period (6 months), remained on monotherapy. Baseline characteristics were similar in th...
متن کاملSartans for hypertension--implications of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Angiotensin receptor blockers (ARBs), also known as sartans, block the activation of angiotensin type 1 receptors and have a recognised role in the treatment of heart failure and nephropathy. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study and the Study on Cognition and Prognosis in the Elderly (SCOPE) were two large clinical trials of ARBs in the treatment of hype...
متن کاملImpact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population.
There has been a lot of interest about new-onset diabetes mellitus in recent hypertension trials, but the implications of diabetes development on cardiac outcomes have not been known. In the Valsartan Antihypertensive Long-Term Use Evaluation trial, 15 245 high-risk patients were followed for an average of 4.2 years. At baseline, 5250 patients were diabetic by the 1999 World Health Organization...
متن کاملThe Valsartan Antihypertensive Long-Term Use Evaluation trial: a study in contrasts.
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial was designed to test the theory in hypertensive patients determined to be at high cardiovascular risk that, for the same level of blood pressure (BP) control, valsartan would reduce cardiac morbidity and mortality more so than amlodipine. The noise level about this trial was high in the months leading up to the release of its...
متن کاملClinical Trial Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide A Randomized Clinical Trial
Many patients with hypertension require 3 agents to achieve target blood pressure (BP). The efficacy/safety of the dual combinations of valsartan (Val)/hydrochlorothiazide (HCTZ) and amlodipine (Aml)/Val in hypertension are well established. This randomized, double-blind study evaluated the efficacy/safety of triple therapy with Aml/Val/ HCTZ for moderate or severe hypertension (mean sitting sy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hypertension
سال: 2000
ISSN: 0895-7061
DOI: 10.1016/s0895-7061(00)00445-3